Know Cancer

forgot password

Biomarkers Serum Collection Methodology Pilot Study

18 Years
75 Years
Not Enrolling
Hemophilia A

Thank you

Trial Information

Biomarkers Serum Collection Methodology Pilot Study

20 adults with severe Hemophilia A seen in one HTC site for routine blood drawing will be
consented for discard blood sampling.

Half of the whole blood discard will be placed in a tiger top test tube, and half of the
whole blood discard sample will be placed in a red top test tube containing exogenously
added recombinant human FVIII concentrate [Advate, Baxter immuno] to assure an end
concentration of once IU per CC of whole blood.

Both whole blood specimens will be allowed to coagulate at room temperature and then will be
centrifuged to prepare serum. The separated serum from each type of collection test tubes
will be aliquoted into eppendorf tubes (a minimum of two aliquots per sample) at a volume of
150 microliters. Aliquoted serum samples will be stored at -70 degrees centigrade and
shipped on dry ice to Synarc Labs.

A panel of standard CTX bone resorption assays will be preformed in duplicate on the two
differently processed serum specimens obtained from each subject.

Results will be analyzed for inter-subject variability using stored age-matched samples
provided by Synarc and intra-subject variability will also be analyzed.

Inclusion Criteria:

- Severe Hemophilia A

Exclusion Criteria:

- If they are not diagnosed with severe hemophilia A.

Type of Study:


Study Design:

Time Perspective: Prospective

Principal Investigator

Craig Kessler, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Georgetown University


United States: Institutional Review Board

Study ID:




Start Date:

December 2010

Completion Date:

May 2011

Related Keywords:

  • Hemophilia A
  • Severe Hemophilia A
  • Hemophilia A Patients
  • Serum collection vs a method of added FVIII to blood samples
  • Hemophilia A



Lombardi Cancer Center Washington, District of Columbia  20007